Zicronapine (fumarate)

Zicronapine (Lu 31-130) fumarate is an antipsychotic medication with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine (Lu 31-130) fumarate has potent antagonistic effects at dopamine D1/D2, and serotonin 5-HT2A receptors[1][2].

Product Specifications

CAS Number

[170381-17-6]

Product Name Alternative

Lu 31-130 (fumarate)

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/zicronapine-fumarate.html

Solubility

10 mM in DMSO

Smiles

O=C(O)/C=C/C(O)=O.CC1(C)N(C)CCN([C@@H]2C[C@@H](C3=CC=CC=C3)C4=C2C=C(Cl)C=C4)C1

Molecular Formula

C26H31ClN2O4

Molecular Weight

470.99

References & Citations

[1]Lopez De Diego, Heidi. et al. Succinate and malonate salts of trans-4- (1R,3S) -6-chloro-3-phenylindan-1-yl) -1,2,2-trimethylpiperazine and their preparation, pharmaceutical compositions, and use as medicaments, particularly as antipsychotics. WO2005016900A1|[2]Lundbeck H. A/S. The clinical phase III programme commenced on zicronapine. 20 Jan 2011.